Abstract:Gastric cancer (GC) is the fifth most common cause of cancer-associated deaths; however, its treatment options are limited. Despite clinical improvements, chemotherapy resistance and metastasis are major challenges in improving the prognosis and quality of life of patients with GC. Therefore, effective prognostic biomarkers and targets associated with immunological interventions need to be identified. Solute carrier family 2 member 2 (SLC2A2) may serve a role in tumor development and invasion. The present study aimed to evaluate SLC2A2 as a prospective prognostic marker and chemotherapeutic target for GC. SLC2A2 expression in several types of cancer and GC was analyzed using online databases, and the effects of SLC2A2 expression on survival prognosis in GC were investigated. Clinicopathological parameters were examined to explore the association between SLC2A2 expression and overall survival (OS). Associations between SLC2A2 expression and immune infiltration, immune checkpoints and IC50 were estimated using quantification of the tumor immune contexture from human RNA-seq data, the Tumor Immune Estimation Resource 2.0 database and the Genomics of Drug Sensitivity in Cancer database. Differential SLC2A2 expression and the predictive value were validated using the Human Protein Atlas, Gene Expression Omnibus, immunohistochemistry and reverse transcription-quantitative PCR. SLC2A2 expression was downregulated in most types of tumor but upregulated in GC. Functional enrichment analysis revealed an association between SLC2A2 expression and lipid metabolism and the tumor immune microenvironment. According to Gene Ontology term functional enrichment analysis, SLC2A2-related differentially expressed genes were enriched predominantly in 'chylomicron assembly', 'plasma lipoprotein particle assembly', 'high-density lipoprotein particle', 'chylomicron', 'triglyceride-rich plasma lipoprotein particle', 'very-low-density lipoprotein particle'. 'intermembrane lipid transfer activity', 'lipoprotein particle receptor binding', 'cholesterol transporter activity' and 'intermembrane cholesterol transfer activity'. In addition, 'cholesterol metabolism', and 'fat digestion and absorption' were significantly enriched in the Kyoto Encyclopedia of Genes and Genomes pathway analysis. Patients with GC with high SLC2A2 expression had higher levels of neutrophil and M2 macrophage infiltration and a significant inverse correlation was observed between SLC2A2 expression and MYC targets, tumor mutation burden, microsatellite instability and immune checkpoints. Furthermore, patients with high SLC2A2 expression had worse prognosis, including OS, disease-specific survival and progression-free interval. Multivariate regression analysis demonstrated that SLC2A2 could independently prognosticate GC and the nomogram model showed favorable performance for survival prediction. SLC2A2 may be a prospective prognostic marker for GC. The prediction model may improve the prognosis of patients with GC in clinical practice, and SLC2A2 may serve as a novel therapeutic target to provide immunotherapy plans for GC.

Downregulation of 425g>a Variant of Calcium-Binding Protein S100A14 Associated with Poor Differentiation and Prognosis in Gastric Cancer.

Calcium-binding Protein S100A14 Induces Differentiation and Suppresses Metastasis in Gastric Cancer.

Calcium-binding Protein S100P and Cancer: Mechanisms and Clinical Relevance

Identification of Significant Biomarkers and Pathways Associated with Gastric Carcinogenesis by Whole Genome-Wide Expression Profiling Analysis

Comprehensive Analysis of the Biological Function and Immune Infiltration of SLC38A2 in Gastric Cancer.

Differential Expression of COL6 Family is a Potential Tumor Marker for Predicting Gastric Cancer

ZNF418 Overexpression Protects Against Gastric Carcinoma and Prompts a Good Prognosis

Elevated THBS2, COL1A2, and SPP1 Expression Levels as Predictors of Gastric Cancer Prognosis.

[Clinical Significance of S100A8 and S100A9 Expression in Gastric Cancer].

S100a6 Overexpression is Associated with Poor Prognosis and is Epigenetically Up-Regulated in Gastric Cancer

ADAMTS19 Suppresses Cell Migration and Invasion by Targeting S100A16 via the NF-κB Pathway in Human Gastric Cancer

Unraveling Molecular Differences of Gastric Cancer by Label-Free Quantitative Proteomics Analysis

S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma

Dual Effects of Targeting S100A11 on Suppressing Cellular Metastatic Properties and Sensitizing Drug Response in Gastric Cancer

The role of the S100A8/S100A9 in gastric tumor progression

Prediction and verification of the prognostic biomarker SLC2A2 and its association with immune infiltration in gastric cancer

Identification and characterization of CLEC11A and its derived immune signature in gastric cancer

Analysis the Prognostic Values of Solute Carrier (SLC) Family 39 Genes in Gastric Cancer

[Regulation Mechanism Study of S100A6 on Invasion and Metastasis in Gastric Cancer].

Downregulation of S100A4 Expression by RNA Interference Suppresses Cell Growth and Invasion in Human Colorectal Cancer Cells.

Expression Status of S100A14 and S100A4 Correlates with Metastatic Potential and Clinical Outcome in Colorectal Cancer after Surgery.